Abstract
Post ERCP pancreatitis is a serious complication that, at the minimum, prolongs hospital stay and, in rare cases, causes serious morbidity and death. The potential for risk reduction has therefore been the matter of extensive research. Rectal Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) were found to be appropriate for clinical use. Pancreatic Duct (PD) stent placement is currently considered the standard of care in high-risk cases where PD entered by guide wire multiple time and contrast injection in to PD. Failure attempt at PD stenting is disastrous. In cases of pancreatic branch duct injuries caused by the PGW combination of PD stenting and rectal NSAIDs should b used because PD stenting alone may not be effective. Sublingual nitroglycerin and bolus-administered somatostatin were found to be promising agents for whom confirmatory research is needed. Additional research required to justify use to prevention of PEP for topical epinephrine, aggressive intravenous fluids and ulinastatin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Liver Research, Disorders & Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
